Asset profile
Olaparib
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: HR+/HER2- Metastatic Breast Cancer (label: Deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic...)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Olaparib: this drug | Approved | Small molecule | PARP | ||
| Talazoparib | Approved | Small molecule | PARP | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Capecitabine | Approved | Small molecule | Fluoropyrimidine (antimetabolite) | ||
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Docetaxel | Approved | Small molecule | Microtubules (tubulin) | ||
| Elacestrant | Approved | Small molecule | Estrogen receptor | ||
| Eribulin Mesylate | Approved | Small molecule | Tubulin / microtubules | ||
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | ||
| Exemestane | Approved | Small molecule | Aromatase | ||
| Fulvestrant (Faslodex) | Approved | Small molecule | Estrogen receptor | ||
| Gedatolisib | Approved | Small molecule | PI3K (class I isoforms) and mTORC1/mTORC2 |
…and 46 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(104 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (8)
November 2026 (1)
Phase 1Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian CarcinomaRecruiting
Est. primary completion 2026-11-01 · NCT04633239 · CT.gov ↗
What to watch
December 2026 (7)
Phase 2Breast Neoplasm, Triple Negative Breast Cancer (TNBC), HRDRecruiting
Est. primary completion 2026-12 · NCT03740893 · CT.gov ↗
What to watch
Phase 2Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma …Active not recruiting
Est. primary completion 2026-12-16 · NCT03375307 · CT.gov ↗
What to watch
Phase 1Solid Tumor, AdultRecruiting
Est. primary completion 2026-12-31 · NCT03772561 · CT.gov ↗
What to watch
Phase 1Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid NeoplasmRecruiting
Est. primary completion 2026-12-31 · NCT04585958 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT03297606 · CT.gov ↗
What to watch
Phase 2Solid Tumor, Precision MedicineRecruiting
Est. primary completion 2026-12-31 · NCT06739395 · CT.gov ↗
What to watch
Phase 2Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal CarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT03579316 · CT.gov ↗
What to watch
2027 (50)
January 2027 (6)
Phase 2Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast CancerRecruiting
Est. primary completion 2027-01 · NCT04683679 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic Ductal Adenocarcinoma, Homologous Recombination Deficiency (HRD)Active not recruiting
Est. primary completion 2027-01 · NCT04666740 · CT.gov ↗
What to watch
Phase 1Neuroendocrine Tumors, Peptide Receptor Radionuclide TherapyRecruiting
Est. primary completion 2027-01-01 · NCT05870423 · CT.gov ↗
What to watch
Phase 2Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, LeiomyosarcomaActive not recruiting
Est. primary completion 2027-01-01 · NCT03851614 · CT.gov ↗
What to watch
Phase 2Squamous Cell Carcinoma of Head and NeckActive not recruiting
Est. primary completion 2027-01-21 · NCT05366166 · CT.gov ↗
What to watch
March 2027 (4)
Phase 1Cancer, Ovarian CancerRecruiting
Est. primary completion 2027-03 · NCT07371104 · CT.gov ↗
What to watch
Phase 2Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer, Renal Carcinoma, Kidney Cancer MetastaticRecruiting
Est. primary completion 2027-03 · NCT03786796 · CT.gov ↗
What to watch
Phase 4Carcinoma, Ovarian EpithelialActive not recruiting
Est. primary completion 2027-03-15 · NCT06121401 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-03-30 · NCT07113964 · CT.gov ↗
What to watch
April 2027 (2)
Phase 1/2Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors, Ovarian CancerNot yet recruiting
Est. primary completion 2027-04 · NCT07453394 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-04-06 · NCT04421963 · CT.gov ↗
What to watch
May 2027 (6)
Phase 2Metastatic Castration-resistant Prostate CancerActive not recruiting
Est. primary completion 2027-05 · NCT06909825 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-05-01 · NCT06488378 · CT.gov ↗
What to watch
Phase 1/2Ovarian Cancer, Epithelial Cancer, Fallopian Tube CancerRecruiting
Est. primary completion 2027-05-01 · NCT07460180 · CT.gov ↗
What to watch
Phase 3Lung Neoplasms, Carcinoma, Non-Small-Cell LungActive not recruiting
Est. primary completion 2027-05-05 · NCT04380636 · CT.gov ↗
What to watch
Phase 2Triple-Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2027-05-30 · NCT07005583 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-05-31 · NCT06545942 · CT.gov ↗
What to watch
June 2027 (4)
Phase 1Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 …Recruiting
Est. primary completion 2027-06-01 · NCT04005690 · CT.gov ↗
What to watch
Phase 2Breast Inflammatory CarcinomaActive not recruiting
Est. primary completion 2027-06-01 · NCT03598257 · CT.gov ↗
What to watch
Phase 1BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation, High Grade Fallopian Tube Serous Adenocarcinoma …Active not recruiting
Est. primary completion 2027-06-27 · NCT03943173 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2027-06-30 · NCT06686745 · CT.gov ↗
What to watch
July 2027 (7)
Phase 1/2Oral Squamous Cell Carcinoma (OSCC)Active not recruiting
Est. primary completion 2027-07 · NCT03085147 · CT.gov ↗
What to watch
Phase 2SCLC,Extensive StageRecruiting
Est. primary completion 2027-07 · NCT05623319 · CT.gov ↗
What to watch
Phase 2Uveal Melanoma, Ocular MelanomaActive not recruiting
Est. primary completion 2027-07 · NCT05524935 · CT.gov ↗
What to watch
Phase 1Glioblastoma, Recurrent Disease, Recurrent GlioblastomaRecruiting
Est. primary completion 2027-07-01 · NCT05432518 · CT.gov ↗
What to watch
Phase 1/2Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine NeoplasmsRecruiting
Est. primary completion 2027-07-01 · NCT04086485 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2027-07-27 · NCT05238922 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-07-31 · NCT05093231 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2ImmunotherapyActive not recruiting
Est. primary completion 2027-08-10 · NCT04169841 · CT.gov ↗
What to watch
Phase 2Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L MutationsRecruiting
Est. primary completion 2027-08-31 · NCT04038502 · CT.gov ↗
What to watch
September 2027 (3)
Phase 1/2Advanced Solid Tumor, Homologous Recombination Deficiency, HRR DeficiencyRecruiting
Est. primary completion 2027-09 · NCT06525298 · CT.gov ↗
What to watch
Phase 1/2Breast Cancer Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Low Breast Carcinoma, Advanced Breast CancerRecruiting
Est. primary completion 2027-09 · NCT06298084 · CT.gov ↗
What to watch
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
October 2027 (6)
Phase 2Platinum-sensitive Ovarian CancerRecruiting
Est. primary completion 2027-10 · NCT06686030 · CT.gov ↗
What to watch
Phase 1/2Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2027-10-22 · NCT02861573 · CT.gov ↗
What to watch
Phase 3Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-10-28 · NCT04624204 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-10-30 · NCT02484404 · CT.gov ↗
What to watch
Phase 1/2Lung Cancer, Extensive-stage Small-cell Lung CancerRecruiting
Est. primary completion 2027-10-31 · NCT06217757 · CT.gov ↗
What to watch
Phase 2Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma …Recruiting
Est. primary completion 2027-10-31 · NCT04858334 · CT.gov ↗
What to watch
December 2027 (10)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12 · NCT05900895 · CT.gov ↗
What to watch
Phase 4HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-01 · NCT07695259 · CT.gov ↗
What to watch
Phase 2Prostate CancerRecruiting
Est. primary completion 2027-12-02 · NCT05568550 · CT.gov ↗
What to watch
Phase 2Renal Cell CancerRecruiting
Est. primary completion 2027-12-30 · NCT03741426 · CT.gov ↗
What to watch
Phase 1/2Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8Active not recruiting
Est. primary completion 2027-12-31 · NCT04728230 · CT.gov ↗
What to watch
Phase 2Ovary CancerRecruiting
Est. primary completion 2027-12-31 · NCT07667751 · CT.gov ↗
What to watch
Phase 2Ovarian CancersNot yet recruiting
Est. primary completion 2027-12-31 · NCT07407452 · CT.gov ↗
What to watch
Phase 2Ovarian Cancer, Fallopian Tube Cancer, Neoadjuvant Treatment, Debulking Surgical ProceduresActive not recruiting
Est. primary completion 2027-12-31 · NCT02489006 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT04090567 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
2028 (24)
January 2028 (6)
Phase 2Malignant Solid NeoplasmsRecruiting
Est. primary completion 2028-01 · NCT02029001 · CT.gov ↗
What to watch
Phase 2Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell LymphomaRecruiting
Est. primary completion 2028-01 · NCT06160843 · CT.gov ↗
What to watch
Phase 2Epithelial Ovarian CancerRecruiting
Est. primary completion 2028-01 · NCT04644289 · CT.gov ↗
What to watch
Phase 2Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)Recruiting
Est. primary completion 2028-01 · NCT07024784 · CT.gov ↗
What to watch
Phase 3Ovarian CancerRecruiting
Est. primary completion 2028-01-21 · NCT05255471 · CT.gov ↗
What to watch
Phase 1BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene MutationActive not recruiting
Est. primary completion 2028-01-31 · NCT06177171 · CT.gov ↗
What to watch
February 2028 (2)
March 2028 (2)
Phase 2Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma …Active not recruiting
Est. primary completion 2028-03-01 · NCT04394858 · CT.gov ↗
What to watch
Phase 2Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm …Active not recruiting
Est. primary completion 2028-03-31 · NCT03682289 · CT.gov ↗
What to watch
April 2028 (2)
June 2028 (4)
Early phase / not applicableTriple Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2028-06-15 · NCT07187674 · CT.gov ↗
What to watch
Phase 1BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative …Active not recruiting
Est. primary completion 2028-06-30 · NCT02208375 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid Tumor, Metastatic Solid TumorRecruiting
Est. primary completion 2028-06-30 · NCT05898399 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast Neoplasms, Triple Negative Breast Cancer, Breast Neoplasms, Breast Cancer, BRCA1 Mutation, BRCA2 Mutation …Recruiting
Est. primary completion 2028-06-30 · NCT05485766 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-08-25 · NCT07156253 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal CarcinomaActive not recruiting
Est. primary completion 2028-10-01 · NCT05554328 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2028-10-30 · NCT05952453 · CT.gov ↗
What to watch
November 2028 (2)
December 2028 (3)
Phase 2/3Castration-resistant Prostate CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07641855 · CT.gov ↗
What to watch
Phase 1Metastatic Castrate Resistant Prostate Cancer (mCRPC)Not yet recruiting
Est. primary completion 2028-12-01 · NCT07090369 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT06201234 · CT.gov ↗
What to watch
2029 (9)
January 2029 (3)
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2029-01-03 · NCT05932862 · CT.gov ↗
What to watch
Phase 1/2Prostatic Neoplasms, Castration-ResistantRecruiting
Est. primary completion 2029-01-15 · NCT06353386 · CT.gov ↗
What to watch
Phase 2Ovary Cancer, Peritoneal Cancer, Fallopian Tube CancerRecruiting
Est. primary completion 2029-01-31 · NCT05887609 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Triple Negative Breast CancerRecruiting
Est. primary completion 2029-06 · NCT06245889 · CT.gov ↗
What to watch
July 2029 (1)
Phase 1/2Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas, Meningioma, Paraganglioma, Pheochromocytoma …Recruiting
Est. primary completion 2029-07 · NCT06607692 · CT.gov ↗
What to watch
December 2029 (4)
Phase 1High Grade Serous Ovarian CancerRecruiting
Est. primary completion 2029-12 · NCT06976892 · CT.gov ↗
What to watch
Phase 1Endometrioid Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube CancerRecruiting
Est. primary completion 2029-12-01 · NCT06856499 · CT.gov ↗
What to watch
Phase 2Recurrent Ovarian Cancer, Platinum-sensitive Ovarian CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07454018 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12-31 · NCT06797635 · CT.gov ↗
What to watch
2030 (7)
January 2030 (2)
March 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-03 · NCT05332561 · CT.gov ↗
What to watch
June 2030 (1)
Phase 3Endometrial Cancer, p53abnRecruiting
Est. primary completion 2030-06 · NCT06712472 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07-01 · NCT05564377 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2Solid TumorNot yet recruiting
Est. primary completion 2030-09-01 · NCT05522491 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
2031 (2)
2032 (1)
October 2032 (1)
Phase 3Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal CarcinomaRecruiting
Est. primary completion 2032-10-31 · NCT06915025 · CT.gov ↗
What to watch
2033 (1)
March 2033 (1)
Phase 3Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast NeoplasmsRecruiting
Est. primary completion 2033-03-23 · NCT06966700 · CT.gov ↗
What to watch
2034 (1)
December 2034 (1)
Phase 3Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma …Recruiting
Est. primary completion 2034-12-31 · NCT06580314 · CT.gov ↗
What to watch
2043 (1)
August 2043 (1)
Phase 3Solid Tumors, Hematologic MalignanciesRecruiting
Est. primary completion 2043-08-04 · NCT03486873 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.